Top Page
AdAlta Ltd.
(Sydney:1AD)
AdAlta Ltd. (1AD) vs. iShares MSCI Australia ETF (EWA)
AdAlta Ltd. Business Overview & Revenue Model
AdAlta Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 677.01K | 677.01K | 1.74M | 3.47M | 2.75M | 848.19K |
| Gross Profit | 457.50K | 457.50K | 1.51M | 3.44M | 2.49M | 848.19K |
| EBITDA | -4.45M | -4.45M | -5.26M | -7.58M | -7.31M | -8.36M |
| Net Income | -4.50M | -4.50M | -5.38M | -4.85M | -6.06M | -5.63M |
Balance Sheet | ||||||
| Total Assets | 2.14M | 2.14M | 5.57M | 7.73M | 10.65M | 9.05M |
| Cash, Cash Equivalents and Short-Term Investments | 1.31M | 1.31M | 3.13M | 4.79M | 8.66M | 5.79M |
| Total Debt | 1.77M | 1.77M | 2.70M | 4.01M | 4.00M | 1.69M |
| Total Liabilities | 2.74M | 2.74M | 3.54M | 5.82M | 5.27M | 2.66M |
| Stockholders Equity | -598.24K | -598.24K | 2.03M | 1.91M | 5.38M | 6.39M |
Cash Flow | ||||||
| Free Cash Flow | -2.94M | -2.94M | -5.32M | -5.13M | -4.11M | -4.78M |
| Operating Cash Flow | -2.94M | -2.94M | -5.26M | -5.13M | -4.09M | -4.78M |
| Investing Cash Flow | 109.61K | 109.61K | -62.40K | -2.13K | -25.23K | -2.12K |
| Financing Cash Flow | 999.06K | 999.06K | 3.67M | 1.27M | 7.02M | 7.19M |
AdAlta Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | AU$7.02M | -1.89 | ― | ― | ― | ― | |
41 Neutral | AU$5.88M | -5.24 | -289.05% | ― | ― | 24.09% | |
40 Underperform | AU$2.17M | -4.33 | -28.49% | ― | ― | 46.43% | |
37 Underperform | AU$6.89M | -1.61 | -628.72% | ― | ― | 31.87% | |
27 Underperform | AU$4.39M | -1.35 | -205.70% | ― | ― | 1.03% |
AdAlta Ltd. Corporate Events
AdAlta Ltd has announced a change in the interests of its director, Tim Oldham, involving the disposal of 1,200,000 unlisted options and 1,396,999 performance rights, while acquiring 1,396,999 ordinary shares. This change reflects a strategic adjustment in the director’s holdings, potentially impacting the company’s stock dynamics and signaling confidence in its future performance.
AdAlta Ltd. announced the cessation of 6,655,000 securities due to the expiry of options or other convertible securities without exercise or conversion as of November 29, 2025. This development may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s financial strategies and market positioning.
AdAlta Limited announced the completion of issuing 401,676,129 ordinary shares and 277,666,667 options, as well as 1,396,999 ordinary shares from employee performance rights. This issuance was conducted without disclosure to investors under specific provisions of the Corporations Act, and the company confirmed compliance with relevant regulatory requirements. The move is part of AdAlta’s strategic financial operations, potentially impacting its market positioning and shareholder value.
AdAlta Ltd. announced the quotation of 388,666,666 fully paid ordinary securities and 194,333,333 options expiring in June 2028 on the ASX. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning and providing opportunities for stakeholders.
AdAlta Ltd. announced the application for quotation of 1,396,999 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of the company’s strategy to enhance its capital structure and support its ongoing development projects, potentially strengthening its market position and offering new opportunities for stakeholders.
AdAlta Ltd. has announced the quotation of new securities on the Australian Securities Exchange (ASX), including 13,009,463 ordinary fully paid shares and 83,333,334 options expiring in June 2028. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially strengthening its market position and providing opportunities for growth and development in its therapeutic offerings.
AdAlta Ltd. announced the cessation of 4,929,060 securities due to the expiry of options or other convertible securities without exercise or conversion as of November 26, 2025. This cessation of securities may impact the company’s capital structure and could have implications for its financial strategy and stakeholder interests.
AdAlta Limited announced that all resolutions at its Annual General Meeting were passed with over 98% support. The company is strategically positioned to dominate the high-growth cellular immunotherapy market, particularly in the treatment of solid tumors, leveraging its innovative approach and strategic partnerships.
AdAlta Limited announced the release of the Chair remarks and CEO presentation at their Annual General Meeting, highlighting their strategic focus on integrating Asian T cell therapy innovations with Western market access. The company aims to dominate the growing cellular immunotherapy market, particularly in treating solid tumors, and is seeking partnerships for its first-in-class fusion protein, AD-214, after successful Phase I clinical studies.
AdAlta Limited announced a change in its registered office and principal place of business to a new address in Hawthorn East, Victoria. This move aligns with the company’s strategic focus on advancing its position in the high-growth cellular immunotherapy market, particularly targeting solid tumors, which remain underserved by current therapies. AdAlta aims to leverage its innovative approaches and strategic partnerships to dominate this market segment.
AdAlta Ltd. announced the cancellation of a previous proposal for a 10-for-1 share consolidation, which was initially set to be discussed at the upcoming Annual General Meeting on November 26, 2025. This decision to withdraw the resolution may impact the company’s stock structure and could influence investor perceptions and market dynamics, as it suggests a reconsideration of strategic financial adjustments.
AdAlta Limited has announced the withdrawal of Resolution 6, which proposed a 10 for 1 share consolidation, from its 2025 Annual General Meeting agenda following guidance from corporate advisors. This decision does not affect the validity of proxy forms for the AGM, where other business items will still be addressed. The move reflects AdAlta’s strategic adjustments as it continues to focus on its core operations in the rapidly growing cellular immunotherapy market, aiming to enhance its positioning and stakeholder value.
AdAlta Ltd. has announced a security consolidation, affecting several of its securities, including ordinary shares and performance rights. This reorganization is set to commence trading on a deferred settlement basis from December 9, 2025, with the record date on December 10, 2025, and the issue date on December 17, 2025. The consolidation is part of the company’s strategic financial restructuring, potentially impacting its market positioning and shareholder value.
AdAlta Ltd has announced a change in the director’s interest, specifically regarding Tim Oldham. The notice details the acquisition of 2,500,000 ordinary shares by Tim Oldham, valued at $8,750. This change reflects an increase in Oldham’s holdings, potentially indicating confidence in the company’s future performance.
AdAlta Limited has completed the issuance of 201,666,666 fully paid ordinary shares at a price of $0.0018 per share. This issuance is part of the company’s funding arrangements with Meurs Group, aimed at addressing outstanding subscription amounts. The shares were issued without disclosure under Part 6D.2 of the Corporations Act, and the company has confirmed compliance with relevant legal provisions. This move is expected to strengthen AdAlta’s financial position and support its ongoing operations in the biotechnology sector.
AdAlta Ltd. has announced the quotation of 201,666,666 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of October 28, 2025. This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning and providing new opportunities for stakeholders.
AdAlta Limited announced the final issuance of shares under its Investment Agreement with the Meurs Group, a longstanding shareholder. This agreement, initiated in April 2024, provided crucial liquidity and strategic flexibility for AdAlta as it developed its cellular immunotherapy strategy. The completion of this share issuance positions AdAlta to raise private capital to advance its CAR-T technologies for solid cancer treatment. The settlement marks the end of the Meurs Investment Agreement, highlighting the continued support from Meurs Group and AdAlta’s readiness to further its market positioning in the high-growth cellular immunotherapy sector.
AdAlta Limited has made significant progress in its ‘East to West’ cellular immunotherapy strategy, with advanced licensing negotiations for its first CAR-T product and plans for a multi-asset collaboration on a second product. The company has strengthened its financial position by raising $1.6 million through market placements and repaying investments, which enhances its negotiating power and potential ownership in its AdCella subsidiary. These developments position AdAlta to leverage its expertise in cellular immunotherapy and expand its market reach, potentially increasing its value and impact in the biotechnology sector.
AdAlta Limited has completed a cash repayment of $405,132 to New Life Sciences Capital (NLSC), settling the remaining balance of their investment agreement without issuing additional shares. This strategic move, facilitated by NLSC’s initial investment, has supported AdAlta’s development of its cellular immunotherapy strategy, positioning the company to advance its CAR-T asset negotiations and raise private capital for global cancer patient treatments.
AdAlta Limited has announced its 2025 Annual General Meeting (AGM) will be held as a hybrid event, allowing shareholders to participate both in-person and virtually. The company emphasizes the importance of shareholder voting and encourages electronic communication to enhance efficiency and sustainability. This approach reflects AdAlta’s commitment to engaging with its stakeholders and adapting to modern communication preferences.
AdAlta Ltd. announced a proposed issue of securities, comprising 183,333,333 options expiring on June 3, 2028, and 366,666,667 fully paid ordinary shares, with a proposed issue date of November 26, 2025. This move is likely to impact the company’s financial positioning by potentially increasing its capital base, which could enhance its ability to fund ongoing and future projects, thereby strengthening its position in the biotechnology sector.
AdAlta Limited has successfully completed the issuance of 153,657,204 fully paid ordinary shares to sophisticated investors through a private placement. This move, announced earlier in October 2025, is part of the company’s strategic efforts to bolster its financial position and support its ongoing research and development initiatives. The issuance was conducted without disclosure to investors under specific provisions of the Corporations Act, and the company has confirmed compliance with relevant legal requirements. This development is expected to enhance AdAlta’s operational capabilities and strengthen its market position in the biotechnology sector.
AdAlta Ltd. announced the quotation of 153,657,204 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 20, 2025. This move is part of previously announced transactions and is expected to enhance the company’s market presence and liquidity, potentially benefiting stakeholders by increasing the accessibility and visibility of its securities.
AdAlta Limited has announced a proposed issue of 153,657,204 ordinary fully paid securities, scheduled for issuance on October 17, 2025. This move is part of a placement or other type of issue, which could have implications for the company’s market positioning and stakeholder interests as it seeks to enhance its capital structure.
AdAlta Ltd. has announced a proposed issue of securities, involving the issuance of 83,333,334 options expiring in 2028 and 13,009,463 fully paid ordinary shares. This strategic move is aimed at raising capital to support the company’s ongoing research and development efforts, potentially enhancing its market position and providing new opportunities for stakeholders.
AdAlta Limited has secured a non-brokered private placement of up to A$0.5 million from a sophisticated Hong Kong investor, enhancing its capacity to pursue its ‘East to West’ cellular immunotherapy strategy. This investment, priced at a 20% premium, underscores confidence in AdAlta’s approach to integrating Asian innovations with Western markets, potentially accelerating the development and licensing of CAR-T cell therapies for solid cancers, and strengthening its market position.
AdAlta Limited has completed the issuance of 76,666,667 fully paid ordinary shares to NLSC, LLC as part of its funding arrangements. This move is part of the company’s strategy to manage its financial obligations and enhance its capital structure, potentially impacting its market positioning and stakeholder relationships.
AdAlta Ltd. has announced the issuance of 76,666,667 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code 1AD. This move is part of previously announced transactions and is expected to enhance the company’s financial position, potentially impacting its market presence and providing additional resources to advance its therapeutic developments.
AdAlta Limited announced that its Annual General Meeting (AGM) will be held on 19 November 2025 as a hybrid event in Melbourne and via Zoom. The meeting will include a business update from CEO Dr. Tim Oldham. The company is strategically positioned to leverage its expertise in cellular immunotherapies to address the underserved solid cancer market, with its innovative products like AD-214 for fibrotic diseases showing promising results in clinical studies. This positions AdAlta to potentially dominate a high-growth market segment.
AdAlta Ltd. has announced the application for quotation of 138,888,889 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, and it signifies a strategic effort to enhance the company’s financial standing and market presence, potentially impacting its operations and industry positioning positively.